LifePoint, Inc. is a development stage company focused on the commercialization of the flow immunosensor technology licensed from the Naval Research Laboratories. This proprietary technology, when used in conjunction with saliva as a non-invasive test specimen using the Company's proprietary collection technology, will allow LifePoint to develop a broadly applicable non-invasive, rapid, on-site diagnostic test system. The product can be used for rapid diagnostic testing for screening (cardiovascular disease, osteoporosis, cancer), rapid testing (heart attack, drug overdose), and therapeutic drug monitoring in non-medical environments such as the workplace, home health care, ambulances, pharmacies, and even law enforcement. The first product under development is for the simultaneous detection of drugs of abuse and alcohol. The market potential for this product is estimated to be $750 million, with marketing planned by the third quarter of 2000.
For more information on LifePoint, Inc. visit www.lifepointinc.com or call (909) 466-8047 x 400.
This press release contains forward-looking statements regarding future events and the future performance of LifePoint, Inc. that involve risks and uncertainties that could cause actual results to differ materially. These risks include, but are not limited to, the early stage of product development, the need for additional funding, the initiation and completion of clinical trials and dependence on third parties for clinical testing and marketing. These risks are described in further detail in the Company's reports filed with the Securities and Exchange Commission.